Drug

TLR7 Agonist CAN1012 clinical trials

Also written CAN1012.

studies test it: 5
open now: 4
in phase 3: 0
first study started: 2022

How each study uses TLR7 Agonist CAN1012 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the TLR7 Agonist CAN1012 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

CAN1012: 5

Studies by the year they started

5 studies that test it; most in 2022 (2)

Studies that test TLR7 Agonist CAN1012, by start year
Year	Studies
2022	2
2024	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Intraductal, Noninfiltrating: 1

Who runs them

Industry 3 · Other 2

Canwell Biotech Limited (2) · Providence Health & Services (2) · CanWell Pharma Inc. (1)

Studies

Open first, then newest update. How each study uses TLR7 Agonist CAN1012 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.